(Q33743658)

29 July 2017

1 reference

title

Genetically derived toxoids for use as vaccines and adjuvants (English)

1 reference

29 July 2017

2

Rappuoli R

1 reference

29 July 2017

Del Giudice G

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 October 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

17 Suppl 2

1 reference

29 July 2017

page(s)

S44-52

1 reference

Cellular microbiology emerging

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

1 reference

7 January 2021

Refined structure of dimeric diphtheria toxin at 2.0 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates functional receptors and diphtheria toxin sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Transmembrane transport of diphtheria toxin, related toxins, and colicins

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Mutation in the structural gene for diphtheria toxin carried by temperate phage .

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

An immunological study of the diphtheria toxin molecule.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Immunogenic correlation between cross-reacting material (CRM197) produced by a mutant of Corynebacterium diphtheriae and diphtheria toxoid

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Toxin inactivation and antigen stabilization: two different uses of formaldehyde

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Protection provided by Haemophilus influenzae type b conjugate vaccines in Los Angeles County: a case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Pertussis Toxin: The Cause of the Harmful Effects and Prolonged Immunity of Whooping Cough. A Hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Bordetella parapertussis and Bordetella bronchiseptica contain transcriptionally silent pertussis toxin genes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

The crystal structure of pertussis toxin

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Site-specific alterations in the B oligomer that affect receptor-binding activities and mitogenicity of pertussis toxin

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Cloning and sequencing of the pertussis toxin genes: operon structure and gene duplication

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Development of a pertussis component vaccine in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Mutants of pertussis toxin suitable for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Co-stimulation of T cells via CD28 inhibits human IgE production; reversal by pertussis toxin

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Role of pertussis toxin A subunit in neutrophil migration and vascular permeability

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: Safety and immunogenicity in 12- to 24- and 2- to 4-month-old children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. The Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Acellular pertussis vaccines containing genetically detoxified pertussis toxin induce long-lasting humoral and cellular responses in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Stage II Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Cellular kinetics of the intestinal immune response to cholera toxoid in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Properties of homogeneous heat-labile enterotoxin from Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

The three-dimensional crystal structure of cholera toxin

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Cholera toxin-catalyzed [32P]ADP-ribosylation of proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Intestinal electrolyte transport and diarrheal disease (1).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Amino acid sequence homology between cholera toxin and Escherichia coli heat-labile toxin

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Identification of errors among database sequence entries and comparison of correct amino acid sequences for the heat-labile enterotoxins of Escherichia coli and Vibrio cholerae

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

An oral B subunit: whole cell vaccine against cholera

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Adjuvant action of cholera toxin and pertussis toxin in the induction of IgA antibody response to orally administered antigen.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Construction and characterization of recombinant Vibrio cholerae strains producing inactive cholera toxin analogs.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Common features of the NAD-binding and catalytic site of ADP-ribosylating toxins.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Role of trypsin-like cleavage at arginine 192 in the enzymatic and cytotonic activities of Escherichia coli heat-labile enterotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Skin immunization made possible by cholera toxin

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: receptor binding is essential and induces differential modulation of lymphocyte subsets

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900234-0

7 January 2021

10.1016/S0264-410X(99)00234-0

Identifiers

DOI

1 reference

29 July 2017

1 reference